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Despite the growing knowledge with regard to the immunomodulatory properties of 
host defense peptides, their impact on macrophage differentiation and on its associated 
microbicidal functions is still poorly understood. Here, we demonstrated that the P17, 
a new cationic antimicrobial peptide from ant venom, induces an alternative phenotype 
of human monocyte-derived macrophages (h-MDMs). This phenotype is characterized 
by a C-type lectin receptors (CLRs) signature composed of mannose receptor (MR) 
and Dectin-1 expression. Concomitantly, this activation is associated to an inflammatory 
profile characterized by reactive oxygen species (ROS), interleukin (IL)-1β, and TNF-α 
release. P17-activated h-MDMs exhibit an improved capacity to recognize and to engulf 
Candida albicans through the overexpression both of MR and Dectin-1. This upreg-
ulation requires arachidonic acid (AA) mobilization and the activation of peroxisome 
proliferator-activated receptor gamma (PPARγ) nuclear receptor through the leukotriene 
B4 (LTB4) production. AA/LTB4/PPARγ/Dectin-1-MR signaling pathway is crucial for 
P17-mediated anti-fungal activity of h-MDMs, as indicated by the fact that the activation of 
this axis by P17 triggered ROS production and inflammasome-dependent IL-1β release. 
Moreover, we showed that the increased anti-fungal immune response of h-MDMs by 
P17 was dependent on intracellular calcium mobilization triggered by the interaction of 
P17 with pertussis toxin-sensitive G-protein-coupled receptors on h-MDMs. Finally, we 
also demonstrated that P17-treated mice infected with C. albicans develop less severe 
gastrointestinal infection related to a higher efficiency of their macrophages to engulf 
Candida, to produce ROS and IL-1β and to kill the yeasts. Altogether, these results 
identify P17 as an original activator of the fungicidal response of macrophages that acts 
upstream PPARγ/CLRs axis and offer new immunomodulatory therapeutic perspectives 
in the field of infectious diseases.
Keywords: Macrophages, host defense peptide, antimicrobial peptides, Candida albicans, c-type lectin receptors, 
arachidonic acid metabolism, PParγ, inflammasome
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inTrODUcTiOn
Antimicrobial peptides (AMPs), also called host defense peptides 
(HDPs), are small molecules produced by all living forms includ-
ing bacteria, insects, plants and vertebrates. These peptides are 
especially found in skin and intestine; thus, they constitute the 
first line of organism immune defense (1). Although HDPs can 
be cationic or anionic, most of them are cationic molecules with 
an amphipatic structure (2).
Unlike antibiotics, cationic HDPs have a microbicidal activ-
ity against a broad spectrum of pathogens including bacteria, 
yeast, and viruses. They exercise their direct antimicrobial effect 
essentially by interacting with negatively charged membranes of 
target cells inducing membrane destabilization and cell death 
(1, 3, 4). These HDPs can also inhibit intracellular pathways 
critical for pathogen survival (5–7). Beside their microbicidal 
activity, most of cationic HDPs exhibit modulatory functions 
on immune cells. HDPs are produced by and act on several 
cell types including innate and adaptive immune cells (8–10). 
Their functions are multiples and depend on their structure, 
the microenvironment, and the target cell. In humans, the 
two main classes of HDPs are cathelicidins and defensins 
(11, 12). LL-37, the only member of the human cathelicidin AMP 
family, is well known to modulate innate and adaptive immune 
responses. Regarding adaptive immune response, this peptide 
induces T lymphocytes chemotaxis and regulates the activation 
of antigen-presenting cells and Th1 polarization of T cells (13). 
This AMP can also contribute to innate immune response by con-
trolling the activation of monocytes, macrophages, and dendritic 
cells (13). Indeed, it was previously described that LL-37 regulates 
cytokine and chemokine genes expression and protein secretion 
in human monocytes and macrophages (14–16). Moreover, 
this AMP promotes directly microbicidal activities of mono-
cytes, macrophages, and neutrophils by increasing pathogen 
phagocytosis and reactive oxygen species (ROS) release (14, 15, 
17–19). This human cathelicidin is also involved in immune cells 
apoptosis, angiogenesis, and wound-healing regulation (20–24). 
Similar to LL-37, immunomodulatory effects on innate immu-
nity were also described for defensins and several HDPs found 
in insect venom (25, 26). Usually, their effects on immune cells 
are mediated through G-protein-coupled receptors (GPCRs). 
Among the HDP-activated GPCRs, the N-formylmethionine-
leucyl-phenylalanine receptors 1 and 2 (FPR1 and FPR2) and the 
chemokine receptors are the most involved (27–30).
Our laboratory has previously isolated two original HDPs 
from ant venom of Tetramorium bicarinatum (31). These pep-
tides, named P16 (Bicarinalin) and P17, are cationic, C-terminal 
amidated, and adopt an α-helix conformation. In this previous 
study, the authors demonstrated a potent and broad antibacte-
rial acti vity for the Bicarinalin (31). Although no microbicidal 
activity for P17 was demonstrated, this HDP could be a good 
candidate to modulate immune response because of its structural 
properties and its low toxicity on human cells.
Despite the growing knowledge with regard to the immu-
nomodulatory properties of HDPs, little is known about how 
they control macrophage differentiation and its associated 
microbicidal functions. Emerging evidence indicates that the 
state of macrophage polarization plays a critical role in the host 
susceptibility against infections. The following two programs 
broadly classify polarized macrophages: classical (M1) and 
alternative (M2) (32, 33). The M1 program arises from type 1 
inflammatory conditions (e.g., IFNγ) and is characterized by 
elevated levels of opsonic receptors. M1 macrophages highly 
produce pro-inflammatory effector molecules, such as reactive 
oxygen and nitrogen species, and pro-inflammatory cytokines 
[interleukin (IL)-1β, TNF-α, IL-6, and IL-12]. These macrophages 
contribute to inflammation and microbial killing. M2 alternative 
macrophages are characterized by abundant levels of the anti-
inflammatory cytokine IL-10 and non-opsonic receptors, such as 
C-type lectin receptors (CLRs) and scavenger receptors. These 
alternative-activated macrophages can also efficiently participate 
to pathogen clearance through CLR-mediated recognition and 
phagocytosis (34–36).
Among the CLRs, Dectin-1 and mannose receptor (MR) of 
the phagocytic system have been described to be essential in anti-
fungal functions of macrophages (34, 35, 37–42).
After binding of β-glucans and mannans, the major cell wall 
components of Candida albicans, these CLRs act in a cooperative 
manner to activate syk-p47phox axis essential to ROS production 
and inflammasome-dependent signaling pathways for IL-1β 
release (35, 36, 43). Thus, the induction of these two CLRs at the 
surface of macrophages is critical for the fungicidal response.
The balance of macrophage differentiation toward an alterna-
tive phenotype, known to highly express MR and Dectin-1, is con-
trolled by the nuclear receptor peroxisome proliferator-activated 
receptor gamma (PPARγ) activation (34, 35, 43). Among PPARγ 
ligands, lipids from the metabolism of arachidonic acid (AA) 
through the COX-1/COX-2 cyclooxygenases and 5- and 12/15- 
lipoxygenases (LOX), are considered to be critical for PPARγ 
endogenous activation (37, 44, 45). We have previously dem-
onstrated that PPARγ activation in macrophages promotes the 
transcription of Dectin-1 and MR and its associated anti-fungal 
functions (34, 43, 46). Although the processes leading to PPARγ 
activation, such as AA release and its subsequent metabolic 
conversion, are important aspects of macrophage alternative 
polarization and CLR-dependent anti-fungal defense, the impact 
of HDPs on this signaling is not yet elucidated.
In the present study, we demonstrated that P17 promotes alter-
native activation of the human monocyte-derived macrophages 
(h-MDMs) characterized simultaneously by a CLRs signature 
composed of MR and Dectin-1 and a pro-inflammatory profile. 
Interestingly, this HDP also improves the recognition and the 
phagocytosis of C. albicans by h-MDMs through the overexpres-
sion of MR and Dectin-1. This upregulation requires AA release 
and the activation of PPARγ through the leukotriene B4 (LTB4) 
production. The activation of AA/LTB4/PPARγ/Dectin-1-MR 
axis by P17 triggers ROS production and inflammasome-depend-
ent IL-1β release critical in the fungicidal activity of P17-activated 
h-MDMs. Finally, we validated the efficiency of P17 to eliminate 
C. albicans in  vivo. Indeed, P17-treated mice infected with C. 
albicans develop less severe gastrointestinal infection related to a 
higher ability of their macrophages to engulf Candida, to produce 
ROS, IL-1β, and to kill C. albicans as compared to untreated mice. 
Altogether, these results identify P17 as an original activator of 
3Benmoussa et al. HDP Promotes Macrophage Anti-Fungal Response
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1650
the fungicidal response of macrophages and support that this 
novel HDP may constitute promising compound to restrain 
fungal infections.
MaTerials anD MeThODs
P17 aMP
The sequence of the P17 peptide (LFKEILEKIKAKL-NH2) 
was characterized by de novo sequencing using mass spec-
trometry and Edman degradation (31). P17 peptide and its 
randomly designed C-terminal amidated scrambled counterpart 
(KIKEEKFLLKLI-NH2) were synthesized on a Liberty microwave 
assisted automated peptide synthesizer (CEM, Saclay, France) 
at a purity grade higher than 99% as previously described (31, 
47). The authenticity and the molecular identity of the synthetic 
peptides were controlled by MALDI-TOF-MS.
Preparation of h-MDMs
Human peripheral blood mononuclear cells were isolated from 
the blood of healthy volunteers by a density gradient centrifuga-
tion method on Lymphoprep (Abcys). Monocytes were isolated 
from mononuclear cells by adherence to plastic for 2 h in special 
macrophage serum-free medium (SFM; Life Technologies) with 
l-glutamine at 37°C in a humidified atmosphere containing 
5% CO2. Non-adherent cells were removed by washing with 
Hanks’ balanced salt solution (HBSS) (Gibco, Invitrogen), and 
the remaining adherent cells (>85% monocytes) were incubated 
in SFM medium. The h-MDMs were obtained after 24  h of 
culture in SFM medium. Adherent h-MDMs were pre-incubated 
30  min or not before the addition of P17 (200  µg/ml) with 
GW9662 (1  nM; Santa Cruz Biotechnology), MAFP (20  µM; 
Calbiochem), MK-886 (10 µM; Calbiochem), N-acetyl-cysteine 
(10 mM; Sigma), or Z-Vad-FMK (ZVAD) (50 µM; Calbiochem) 
for 30 min.
C. albicans strains
The strain of C. albicans used throughout these experiments was 
isolated from a blood culture of a patient in the Toulouse-Rangueil 
University Hospital (98/26135). The isolate was identified as C. 
albicans based on common laboratory criteria and cultured on 
Sabouraud dextrose agar (SDA; Biorad, Hercules, CA, USA) 
plates containing gentamicin and chloramphenicol. C. albicans 
was maintained by transfers on SDA plates. Growth from an 
18- to 24-h SDA culture of C. albicans was suspended in sterile 
saline buffer (HBSS; Life Technologies). In all experiments, the 
h-MDMs were challenged with blastospores.
Killing assay
Human monocyte-derived macrophages were treated with P17 
(200  µg/ml) for 24  h and were allowed to interact for 40  min 
at 37°C with C. albicans blastospores (at a ratio of 0.3 yeast per 
macrophage) as previously described (36, 40). Unbound yeasts 
were removed by four washes with medium. h-MDMs were 
then incubated at 37°C for 4  h. After incubation, the medium 
was removed and cells were lysed. The CFU of C. albicans were 
quantified after plating on Sabouraud plates for 24–48 h at 37°C.
In some experiments, monocyte-derived macrophages 
were incubated with 1  µg per well of MR siRNA (Santa Cruz 
Biotechnology sc-45360) and/or Dectin-1 siRNA (Santa Cruz 
Biotechnology sc-63276) for 6 h into siRNA transfection medium 
(siRNA reagent system, Santa Cruz Biotechnology sc-45064) 
according to the manufacturer’s instructions before the addition 
of P17.
Binding and Phagocytosis assay
Human monocyte-derived macrophages were treated with P17 
(200 µg/ml) for 24 h and were then challenged with GFP-labeled 
yeasts at a ratio of 6 blastospores per macrophage. In some experi-
ments, the monocyte-derived macrophages were incubated at 
4°C for 20 min with 500 µg/ml of mannans and/or laminarins 
before the addition of the yeasts. The binding was performed at 
4°C and the phagocytosis was initiated at 37°C. The number of 
C. albicans bound or engulfed by macrophages was determined 
by fluorescence quantification using the Envision fluorimetry-
based approach (Perkin Elmer).
assay for rOs Production
Human monocyte-derived macrophages were treated with P17 
(200  µg/ml) for 24  h and ROS production was measured by 
chemiluminescence in the presence of 5-amino-2,3-dihydro-1, 
4-phthalazinedione (luminol; Sigma) using a thermostatically 
(37°C) controlled luminometer (Envision; Perkin Elmer). The 
generation of chemiluminescence was monitored continu-
ously for 1 h and 30 min after challenge or not with C. albicans 
blastospores (yeast-to-macrophage ratio: 3:1). Statistical analysis 
was performed using the area under the curve expressed in 
counts × seconds.
elisa cytokine Titration
Human monocyte-derived macrophages were treated with P17 
(200 µg/ml) for 24 h and challenged with C. albicans blastospores 
at a ratio of 3 yeasts per macrophage for 8 h. The release of TNF-α, 
IL-1β, IL-12, and IL-10 in the cell supernatants was determined 
with a commercially available OptiEIA kit (BD Biosciences) 
according to the manufacturer’s instructions.
Western Blot analysis
Human monocyte-derived macrophages were treated with P17 
(200  µg/ml) for 24  h and challenged for 8  h with C. albicans 
blastospores at a ratio of 3 yeasts per macrophage. h-MDMs 
were lysed with RIPA buffer (Sigma) and protein extracts were 
separated in SDS-PAGE as previously described (37). After pro-
tein transfer, membranes were incubated overnight at 4°C with a 
rabbit anti-phosphorylated p47phox (Assay biotechnology, A1171; 
1/260), a rabbit anti-caspase-1 (Biovision, 3019-100; 1/100), or a 
goat anti-GAPDH antibody (Cell Signaling, #5174; 1/1,000) and 
then for 1 h at room temperature with a peroxidase conjugated 
secondary antibody. Membranes were washed, and proteins of 
interest were visualized with WesternBright™ ECL (Advansta) 
or the SuperSignal West Pico Chemiluminescent Substrate 
(ThermoScientific) for the GAPDH. Images have been cropped 
for presentation.
TaBle 1 | Human primer sequences used in qPCR analysis.
gene 5′–3′ sequence
Alox5 Antisense ACT-GGA-AAC-ACG-GCA-AAA-AC
Sense TTT-CTC-AAA-GTC-GGC-GAA-GT
Itgam (CD11b) Antisense TTG-CAT-CCA-TCT-CAA-ATC-CA
Sense CTC-CCA-AAG-TGC-TGG-GAT-TA
Fcgr3 (CD16) Antisense TAC-AGC-GTG-CTT-GAG-AAG-GA
Sense GCA-CCT-GTA-CTC-TCC-ACT-GT
Fcgr2 (CD32) Antisense CCA-AAG-GCT-GTG-CTG-AAA-CT
Sense TAC-TCC-CCG-CTG-TCA-TTG-TT
Cd36 Antisense TGA-TAG-GTG-CAG-CAA-AGC-AC
Sense TGT-AAC-CCA-GGA-CGC-TGA-GG
Clec7a (Dectin-1) Antisense CCA-AGC-ATA-GGA-TTC-CCA-AAA
Sense AAA-AGG-ATC-GTG-TGC-TGC-ATC
Ptgs2 (COX-2) Antisense TGA-GCA-TCT-ACG-GTT-TGC-TG
Sense TGC-TTG-TCT-GGA-ACA-ACT-GC
Pla2g4a (cPLA2) Antisense GCC-TTG-GTG-AGT-GAT-TCA-GCT
Sense AGA-TTC-AAG-CCC-AGC-ATG-AAG
Cd209 (DC-SIGN) Antisense GGG-CAT-GGA-GGC-TCC-AC
Sense CAA-CTT-AGA-AAC-AGC-CAA-ATG-GAA
Alox5ap (FLAP) Antisense ACC-CGC-TCA-AAG-GCA-ATG-G
Sense CAC-GAA-AGC-AGG-ACC-CAG-A
Gapdh Antisense AGG-TCG-GAG-TCA-ACG-GAT-TT
Sense ATC-TCG-CTC-CTG-GAA-GAT-GG
Il1b Antisense CAG-CCA-ATC-TTC-ATT-GCT-CA
Sense AGG-CAG-AGA-GGG-AAG-GAG-AG
Il6 Antisense TAC-CCC-CAG-GAG-AAG-ATT-GT
Sense TTT-TCT-GCC-AGT-GCC-TCT-TT
Il12 Antisense TGG-GTG-GGT-CAG-GTT-TGA-TG
Sense GCC-CAG-CTG-CTG-AGG-AGA-GT
Il10 Antisense TGC-AAA-ACC-AAA-CCA-CAA-GA
Sense TCT-CGG-AGA-TCT-CGA-AGC-AT
Il1ra Antisense TGG-GAA-TCT-CAG-ATG-GGA-AG
Sense CTG-TGT-CCC-CCA-GAA-CTT-GT
Tgfb1 Antisense ACT-GAG-GGG-AAG-GGA-CAA-CT
Sense TCG-GTA-CCA-GGT-GAG-GGT-AG
p47phox Antisense CCT-CAT-TGT-CCA-GTG-TGG-TG
Sense TCT-TCC-GTC-TCG-TCA-GGA-CT
Lta4h Antisense ACT-GCT-TGG-AGG-ACC-AGA-GA
Sense GGA-AAG-CAT-TAG-CAG-GCA-AG
Mrc1 (MR) Antisense GGC-GGT-GAC-CTC-ACA-AGT-AT
Sense ACG-AAG-CCA-TTT-GGT-AAA-CG
Ptges (PGES) Antisense CAT-GTG-AGT-CCC-TGT-GAT-GG
Sense GAC-TGC-AGC-AAA-GAC-ATC-CA
Pparg Antisense GCT-GTG-CAG-GAG-ATC-ACA-GA
Sense GGG-CTC-CAT-AAA-GTC-ACC-AA
Tnfα Antisense TCC-TTC-AGA-CAC-CCT-CAA-CC
Sense AGG-CCC-CAG-TTT-GAA-TTC-TT
4
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Flow cytometry
Human monocyte-derived macrophages were treated with P17 
(200 µg/ml) for 24 h and then incubated with ice-cold PBS and gently 
scraped. Collected cells were centrifuged at 1,500 rpm for 10 min, 
and the cell pellet was suspended in PBS medium supplemented 
with 1% fetal calf serum (FCS). Surface expressed MR, Dectin-1, 
DC-SIGN, CD16, or CD36 was detected, respectively, using PerCP-
Dectin-1 monoclonal antibody (mAb; R&D FAB1859C-100, 1/40), 
PE-DC-SIGN (mAb; BD Biosciences 551 265, 1/20), FITC-CD16 
(mAb; PNIM 0814, 1/20), or APC-CD36 monoclonal antibodies 
(mAb; BD Biociences 550 956, 1/40). To evaluate the MR surface 
expression, we have used MR-specific ligand conjugated with FITC 
(Sigma A7790, 1 mg/ml, 1/100). All staining were performed on 
PBS−/− 1% FCS medium. A population of 10,000 cells was analyzed 
for each data point. All analyses were carried out in a Becton 
Dickinson FACScalibur using the FACSDiva version 6.2 software.
reverse Transcription and real-time Pcr
Human monocyte-derived macrophages were treated with P17 
(200 µg/ml) and/or LTB4 (100 nM; Cayman Chemical Company) 
for 8 h.
The mRNA preparation was made using the EZ-10 Spin 
Column Total RNA Minipreps Super Kit (Bio Basic) using the 
manufacturer’s protocol. Synthesis of cDNA was performed 
according to the manufacturer’s recommendations (Thermo 
electron). RT-qPCR was performed on a LightCycler 480 system 
using LightCycler SYBR Green I Master (Roche Diagnostics). The 
primers (Eurogentec) were designed with the software Primer 3. 
GAPDH mRNA was used as the invariant control. Serially diluted 
samples of pooled cDNA were used as external standards in each 
run for the quantification. Primer sequences are listed in Table 1.
aa Mobilization and eia lipid 
Quantification
Human monocyte-derived macrophages were pre-labeled with 
[3H]AA. Briefly, h-MDMs (5 × 105 per well in 48-well plates) were 
cultured for 18 h at 37°C in the presence of P17 (200 µg/ml) and 
1 μCi/ml [3H]AA. The culture medium was then removed and 
pre-labeled macrophages were washed three times with 0.5  ml 
SFM. The cells were challenged with C. albicans blastospores at a 
ratio of 3 yeasts per macrophage for 2 h. The [3H]AA metabolites 
released into the culture medium were quantified by measurement 
of the radioactivity by beta liquid scintillation counting using a 
1217 Wallac Rackbeta LKB 1217, as previously described (37).
Determination of intracellular calcium 
concentration
Intracellular calcium concentration was measured using the 
fluorescent probe Fluo 3-AM (Molecular Probe). Briefly, h-MDMs 
(1.5 ×  105) were incubated with 11.5 ×  10−6 M Fluo 3-AM for 
30 min at 37°C. The time course of the intracytosolic Ca2+ level 
was recorded every 0.5 s for a total period of 3 min after the addi-
tion of P17 (200 µg/ml). In desensitization experiments, a second 
injection of bacterial N-formylmethionine-leucyl-phenylalanine 
peptide (fMLP) or P17 was performed at the end of fluorescence 
record and the time course of the intracytosolic Ca2+ level was 
recorded for supplemental 3 min. In some experiments, h-MDMs 
were pre-incubated with U73122 (2  µM) or with calcium-free 
HBSS for 10 min before the addition of P17. Fluorescence was 
quantified using the Envision fluorimetry-based approach 
(Perkin Elmer).
In Vivo experiment
Male mice aged 12 weeks on C57BL/6 background were used for 
in vivo experiments. Mice were bred and handled by the protocols 
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approved by the Conseil Scientifique du Centre de Formation et 
de Recherche Experimental Medico Chirurgical and the ethics 
board of the Midi-Pyrénées ethic committee for animal experi-
mentation (Approval no B3155503). All cages were changed twice 
weekly, and all manipulations of the animals were carried out in 
a laminal blow hood under aseptic conditions. The photoperiod 
was adjusted to 12  h light and 12  h dark. C57BL/6 mice were 
purchased from Janvier (France).
The gastrointestinal infection (GI) with the C. albicans 
was established by oral infection with 50 × 106 C. albicans per 
mouse. To establish esophageal and GI candidiasis in mice, we 
performed intra-esophageal infection with 5 × 107 viable cells 
of C. albicans in sterile saline solution. No antibiotic or immu-
nosuppressive treatment was used to facilitate mucosal infection 
by C. albicans of the oral cavity and GI tract.
Mice were treated intraperitoneally with P17 (10  µg per 
mouse) 1 day before the day of the infection with C. albicans and 
then every 2 days (four injections). Control groups received saline 
solution. Therapeutic studies were performed on separate groups 
of six mice infected with C. albicans treated or not with P17.
The body weight of each mouse was recorded daily, and the 
condition of each mouse was assessed twice daily. Feces were col-
lected on days 4 and 5 post-infections. At day 6 post-infection, 
all mice were euthanized using CO2 asphyxia and the cecum and 
colon were aseptically removed to evaluate C. albicans coloniza-
tion. To quantify the number of viable C. albicans in cecum, 
colon, and feces, each tissue sample removed was mechanically 
homogenized in 1 ml of saline with 100 U of penicillin/ml and 
100 µg of streptomycin/ml. Serial dilutions of homogenate were 
plated onto SDA for quantitative determination of the number of 
C. albicans in the tissue samples. Plates were incubated at 37°C for 
1–2 days and the number of colonies was counted.
After euthanasia, resident peritoneal cells were harvested by 
washing the peritoneal cavity with 5 ml of sterile 199 medium 
with Hanks’ salts as previously described (6). Collected cells 
were centrifuged at 400 ×  g for 8  min, and the cell pellet was 
suspended in SFM optimized for macrophage culture (Invitrogen 
Life Technologies). Cells were allowed to adhere for 2 h at 37 C 
and 5% CO2. Non-adherent cells were then removed by washing 
with HBSS. The macrophage monolayers were used to investigate 
their capacity to bind, to engulf and to kill C. albicans, and to 
produce ROS and IL-1β in response to yeast challenge.
statistical analysis
For each experiment, the data were subjected to one-way analysis 
of variance followed by the means multiple comparison method 
of Bonferroni–Dunnett. p < 0.05 was considered as the level of 
statistical significance.
resUlTs
P17 Promotes alternative activation  
of h-MDMs characterized by an 
inflammatory signature
In order to assess the impact of P17 in h-MDMs differentiation, 
we evaluated the expression of specific markers of classical and 
alternative activation in P17-treated h-MDMs. Overall, P17-
treated h-MDMs displayed a downregulation of membrane 
receptors characteristics of classical M1 polarization, such as 
CD11b (Itgam), CD16 (Fcgr3), and CD32 (Fcgr2), which was 
mirrored by an upregulation of MR (Mrc1), Dectin-1 (Clec7a), 
DC-SIGN (Cd209), and CD36 (Cd36) alternative activation 
markers (Figure  1A). This finding was further supported by 
the reciprocal increase of anti-inflammatory IL-10 (Il10), IL-1 
receptor antagonist (Il1ra), TGFβ (Tgfb1), CCL-17 (Ccl17), and 
CCR2 (Ccr2) and reduction of IL-12 (Il12) and CCL-2 (Ccl2) 
mRNA expression. Moreover, consistent with increased mRNA 
encoding alternative M2 activation markers, protein levels of MR, 
Dectin-1, and IL-10 were significantly increased (Figures 1B,C). 
The acquisition of this alternative phenotype upon P17 activa-
tion is reinforced by the strong decrease of IL-12 protein level 
(Figure  1C). We observed unaffected protein amounts for 
DC-SIGN, CD16, and CD36 (Figure 1B).
Surprisingly, the increase in alternative markers in P17-treated 
h-MDMs was accompanied by an inflammatory signature, as 
demonstrated by an augmentation in the mRNA level of the 
pro-inflammatory cytokines IL-1β (Il1b), TNF-α (Tnfα), and 
IL-6 (Il6). Consistently, the production of IL-1β and TNF-α was 
also induced in P17-treated h-MDMs (Figure 1C). In line with 
increased IL-1β production in P17-treated h-MDMs, the process-
ing of pro-caspase-1 into its p20 subunit, which is a hallmark of 
caspase-1 activation, was significantly increased in P17-treated 
h-MDMs, demonstrating that the caspase-1-induced IL-1β 
release is activated by P17 (Figure 1D).
To further explore the pro-inflammatory impact of P17 on 
h-MDMs, we next assessed ROS production by P17-treated 
h-MDMs. We demonstrated that ROS release was strongly 
increased in P17-treated h-MDMs (Figure  1E). In line, the 
mRNA level and the amount of phosphorylated p47phox, a cyto-
solic subunit of the NADPH oxidase complex whose activation is 
essential to ROS release, were significantly increased in h-MDMs 
activated by P17 (Figures 1F,G).
Taken together, these results indicated that P17 induces an 
alternative phenotype characterized simultaneously by a CLRs 
signature composed of MR and Dectin-1 and a pro-inflammatory 
profile.
P17 induces Mr and Dectin-1 expression 
on h-MDMs through PParγ activation 
Dependent on lTB4 Production
The nuclear receptor PPARγ is a key component of the signaling 
pathway leading to alternative activation of macrophages and 
directly controls the expression of CLRs (34–36). To identify 
how P17 may have an impact on MR and Dectin-1 overexpres-
sion, we evaluated whether P17 can regulate PPARγ activation. 
The mRNA levels of PPARγ (Pparg) and of its target gene SRB1 
(Scarb1) were significantly increased in P17-treated h-MDMs, 
suggesting that P17 improved PPARγ activation.
To further explore whether P17-induced PPARγ activa-
tion was involved in MR and Dectin-1 overexpression, we 
evaluated the gene expression of these two CLRs in the pres-
ence of GW9662, a selective PPARγ antagonist. The treatment 
FigUre 1 | P17 mediates an alternative phenotype of human monocyte-derived macrophages (h-MDMs) characterized by C-type lectin receptor (CLR) and 
inflammatory signatures. (a) Gene expression analysis of markers of classical and alternative polarization in h-MDMs treated or not with P17. The results were 
represented in fold induction relative to the untreated h-MDMs control. (B) Mannose receptor (MR), Dectin-1, DC-SIGN, CD16, and CD36 protein expressions in 
h-MDMs treated or not with P17. Graphs represent geomean fluorescence quantification for the indicated proteins. (c) TNF-α, interleukin (IL)-1β, IL-12, and IL-10 
release by h-MDMs treated or not with P17 after challenge with Candida albicans. (D) Immunoblot analysis of caspase-1 p20 fragment cleavage in h-MDMs treated 
or not with P17 after C. albicans challenge. Band intensity was quantified using the ImageJ software and was represented as the ratio between the band intensities 
of p20 and of pro-caspase-1. (e) Reactive oxygen species production by h-MDMs treated or not with P17 after challenge with C. albicans. (F) Gene expression of 
P47phox in h-MDMs treated or not with P17. The results were represented in fold induction relative to the untreated h-MDMs control. (g) Phosphorylated p47phox 
immunoblot after C. albicans challenge in h-MDMs treated or not with P17. Band intensity was quantified using the ImageJ software and was represented as the 
ratio between the band intensities of phosphorylated p47phox and of P47phox. Results correspond to mean ± SEM of triplicates. Data are representative of three 
independent experiments. *p < 0.05, **p < 0.01 compared to the respective untreated control.
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of P17-activated h-MDMs with GW9662 inhibited Mrc1 and 
Clec7a gene overexpressions, demonstrating that PPARγ is criti-
cally required for P17-induced Dectin-1 and MR expression on 
human h-MDMs (Figure 2A).
Peroxisome proliferator-activated receptor gamma is 
activated by endogenous ligands derived from AA (34, 35, 
43, 48). The COX-1/2 cyclooxygenase, 5- and 12/15-LOX are 
considered to be critical for the conversion of AA into endog-
enous PPARγ ligands. To assess whether P17 can coordinate 
PPARγ ligand availability, we evaluated the gene expression of 
enzymes involved in both COX and LOX signaling pathways. 
The mRNA levels of cPLA2 (Pla2g4a), enzyme needed for AA 
release from membrane phospholipids, 5-LOX (Alox5), FLAP 
(5-LOX activating enzyme) (Alox5ap), and LTA4 hydrolase 
(Lta4h), critical for LTB4 synthesis, were strongly increased in 
P17-treated h-MDM (Figure 2B). Moreover, the mRNA levels 
of COX-2 (Ptgs2), PGES (Ptges), and 15-LOX (Alox15) were not 
differentially expressed in untreated and P17-treated h-MDMs, 
supporting that P17 had no incidence on COX-2 and 12/15-LOX 
signaling pathways.
Then, we determined whether these effects on gene expres-
sion also translate into changes in ligand availability. Consistent 
with cPLA2 gene overexpression, the mobilization of AA was 
induced in P17-treated h-MDMs (Figure 2C). Furthermore, in 
line with LTA4 hydrolase expression in P17-treated h-MDMs, 
we observed strong increase of LTB4 release (Figure 2D). These 
data suggest that the generation of LTB4 metabolites by h-MDMs 
upon P17 treatment is dependent both on AA mobilization and 
metabolism.
To confirm that P17 positively regulates MR and Dectin-1 
expressions through the AA metabolism, we determined Mrc1 
and Clec7a gene expression in the presence of MAFP, a spe-
cific cPLA2 inhibitor, and MK-886, a FLAP inhibitor, which 
prevents 5-LOX activation. The increase of MR and Dectin-1 
mRNA levels in P17-treated h-MDMs was completely lost in the 
presence of MAFP and MK-886 (Figure 2E), further supporting 
FigUre 2 | P17 promotes C-type lectin receptor (CLR) expression on human monocyte-derived macrophages (h-MDMs) through leukotriene B4 (LTB4)-mediated 
peroxisome proliferator-activated receptor gamma (PPARγ) activation. (a) Gene expression analysis of PPARγ, SRB1, mannose receptor (MR), and Dectin-1 in 
h-MDMs treated or not with P17, in the presence of a selective PPARγ antagonist GW9662. The results were represented in fold induction relative to the untreated 
h-MDMs control. (B) Gene expression analysis of arachidonic acid metabolic enzymes in h-MDMs treated or not with P17. The results were represented in fold 
induction relative to the untreated h-MDMs control. (c) [3H]AA mobilization in membrane phospholipids of h-MDMs treated or not with P17. (D) LTB4 production by 
h-MDMs treated or not with P17. (e) Gene expression analysis of MR and Dectin-1 in h-MDMs treated or not with P17, in the presence of MAFP, a specific cPLA2 
inhibitor, and MK-886, a FLAP inhibitor, which prevents 5-LOX activation. The results were represented in fold induction relative to the untreated h-MDMs control.  
(F) Gene expression analysis of MR, Dectin-1, SRB1, and CD36 in h-MDMs treated or not with P17, in the presence of MAFP and/or LTB4. The results were 
represented in fold induction relative to the untreated h-MDMs control. Results correspond to mean ± SEM of triplicates. Data are representative of three 
independent experiments. *p < 0.05, **p < 0.01 compared to the respective untreated control.
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that P17 controls MR and Dectin-1 expressions through AA 
metabolism.
Peroxisome proliferator-activated receptor gamma activity, 
as determinate by the induction of MR-, Dectin-1- and SRB1-
specific PPARγ target genes, was increased similarly with P17 
and LTB4 (Figure  2F). Furthermore, the addition of both P17 
and LTB4 did not showed any additive effect, suggesting that 
P17 regulates MR and Dectin-1 surface expression by controlling 
PPARγ activation through the LTB4 production. Interestingly, 
the inhibition of P17-induced PPARγ target genes expression by 
MAFP was restored by the addition of LTB4, clearly establishing 
that P17-mediated PPARγ activation through LTB4 synthesis. 
Overall these data showed that P17 induces alternative activa-
tion of h-MDMs characterized by Dectin-1 and MR expressions 
through LTB4-mediated PPARγ activation.
P17 improves Fungicidal Properties  
of h-MDM through aa/lTB4/PParγ/ 
Mr-Dectin-1 signaling
Previous works from our laboratory established the importance of 
alternative activation in the fungicidal functions of macrophages 
(34, 35, 43). On the basis of the current findings demonstrating 
an effect for P17 on alternative polarization, we next investigated 
whether P17-treated h-MDMs could have an impact on the 
C. albicans clearance. P17 did not exhibit an effective anti-fungal 
activity against C. albicans relative to the conventional ampho-
tericin B anti-fungal agent. Furthermore, the association of 
P17 with amphotericin B did not improve the AMB anti-fungal 
activity, supporting that this peptide could not be used as a direct 
anti-fungal agent (Figure S1A in Supplementary Material). 
After P17 treatment, h-MDMs showed a robust increase in 
their ability to kill C. albicans, demonstrating that P17 promotes 
macrophage-intrinsic anti-fungal activity and supporting the use 
of P17 as a promising immunomodulatory compound to restrain 
fungal infections (Figure 3A). Consistent with our observation, 
P17-treated h-MDMs were more efficient to bind and to engulf 
C. albicans (Figures 3B,C). Interestingly, the induction of ROS 
production by P17 is essential in in  vitro fungicidal activity of 
P17-activated h-MDMs, since the use of antioxidant N-acetyl 
cysteine (NAC) totally abolished the fungicidal effect of P17-
treated h-MDMs against C. albicans (Figure 3D).
Then, we examined whether ROS production, which act 
as a common cellular signal upstream of the inflammasome 
activation (49), was responsible for IL-1β induction by P17 in 
response to Candida. While the antioxidant NAC suppressed 
FigUre 3 | P17 improves anti-fungal properties of human monocyte-derived macrophages (h-MDMs) through AA/LTB4/peroxisome proliferator-activated receptor 
gamma (PPARγ)/Dectin-1-MR signaling pathway. (a) Killing assay of h-MDMs treated or not with P17 incubated with Candida albicans. Binding (B) and 
phagocytosis (c) of C. albicans by h-MDMs treated or not with P17. (D) Killing assay of h-MDMs treated or not with P17 incubated with C. albicans in presence of 
antioxidant N-acetyl cysteine (NAC). (e) Interleukin (IL)-1β release by h-MDMs treated or not with P17 after C. albicans challenge in presence of antioxidant N-acetyl 
cysteine (NAC). The results were represented in fold induction relative to the respective untreated h-MDMs control. (F) Reactive oxygen species (ROS) production by 
h-MDMs treated or not with P17 after C. albicans challenge in presence of caspases inhibitor ZVAD. The results were represented in fold induction relative to the 
respective untreated h-MDMs control. (g) Killing assay of h-MDMs treated or not with P17 incubated with C. albicans in presence of a selective PPARγ antagonist 
(GW9662), a specific inhibitor of arachidonic acid (AA) mobilization (MAFP), or of an inhibitor of 5-LOX activation (MK-886). ROS (h) and IL-1β (i) production by 
h-MDMs treated or not with P17 after C. albicans challenge in presence of a selective PPARγ antagonist (GW9662), a specific inhibitor of AA mobilization (MAFP), or 
of an inhibitor of 5-LOX activation (MK-886). The results were represented in fold induction relative to the respective untreated h-MDMs control. (J) Immunoblot 
analysis of caspase-1 p20 fragment cleavage in h-MDMs treated or not with P17 after C. albicans challenge in presence of a specific inhibitor of AA mobilization 
(MAFP) or of 5-LOX activation inhibitor (MK-886). Band intensity was quantified with Image J software and was represented as the ratio between the band intensities 
of p20 and of pro-caspase-1. (K) Killing assay of h-MDMs silenced for Dectin-1 and/or mannose receptor (MR) treated or not with P17 after C. albicans challenge. 
(l) Binding of C. albicans by h-MDMs treated or not with P17 in presence of mannan and/or laminarin. The results were represented in fold induction relative to the 
respective untreated h-MDMs control. (M) ROS production by h-MDMs silenced for Dectin-1 and MR treated or not with P17 after C. albicans challenge. The results 
were represented in fold induction relative to the respective untreated h-MDMs control. Results correspond to mean ± SEM of triplicates. Data are representative of 
three independent experiments. *p < 0.05, **p < 0.01 compared to the respective untreated control.
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Candida-induced IL-1β secretion by P17-activated h-MDMs, the 
inhibition of caspase activation by the addition of ZVAD did not 
change ROS production by P17-activated h-MDMs after Candida 
challenge (Figures 3E,F). Therefore, these results showed that in 
response to Candida, ROS production occurred upstream of the 
caspase-1-induced IL-1β production.
To determine whether P17-mediated PPARγ activation 
depen dently on LTB4 synthesis was involved in fungicidal activ-
ity of P17-treated h-MDMs, we evaluated their ability to kill C. 
albicans in the presence of a selective PPARγ antagonist GW9662, 
a specific inhibitor of AA mobilization MAFP, or an inhibitor of 
5-LOX activation MK-886. The increased capacity of P17-treated 
h-MDMs to kill C. albicans was totally inhibited in presence of 
GW9662, MAFP, and MK-886 (Figure 3G). Consistent with these 
findings, the addition of these inhibitors abolished P17-mediated 
ROS, IL-1β release, and caspase-1 activation of h-MDMs in 
response to C. albicans (Figures 3H–J).
To explore whether the increased expression of Dectin-1 and 
MR on P17-treated h-MDMs has any functional consequence 
in C. albicans elimination, we assessed the ability of P17-treated 
h-MDMs deficient for Dectin-1 and/or MR to kill the yeast. The 
gene silencing for Dectin-1 and/or MR in P17-treated h-MDMs 
resulted in the abolition of the ability of these cells to kill more 
efficiently C. albicans (Figure 3K). In terms of recognition of C. 
albicans, the pre-treatment of P17-activated h-MDMs with solu-
ble MR and Dectin-1-blocking agents (mannan and/or lamina-
rin, respectively) abrogated the increased capacity for P17-treated 
h-MDMs to interact with the yeast (Figure 3L). Moreover, this 
pre-treatment totally abolished the induction of ROS production 
after C. albicans challenge (Figure 3M).
FigUre 4 | P17 controls anti-fungal properties of human monocyte-derived macrophages (h-MDMs) via the induction of intracellular calcium mobilization 
dependent on pertussis toxin (PTX)-sensitive G-protein-coupled receptor interaction. Intracellular calcium concentration in h-MDMs treated or not with P17 using 
fluorescent probe Fluo 3-AM. (a) Calcium concentration in h-MDMs treated or not with P17 in the presence of calcium-deprived medium [Hank’s balanced salt 
solution (HBSS-)] and an inhibitor of the intracellular pools calcium release (U73122). (B) Calcium concentration in h-MDM treated or not with P17 in the presence of 
PTX. (c) Calcium concentration in h-MDMs treated or not with P17 after desensitization of N-formylmethionine-leucyl-phenylalanine peptide receptors. (D) Killing 
assay of h-MDMs treated or not with P17 incubated with Candida albicans in the presence of calcium chelator (BAPTA-AM). Reactive oxygen species (e) and 
interleukin-1β (F) release by h-MDMs treated or not with P17 in the presence of calcium chelator (BAPTA-AM) after C. albicans challenge. The results were 
represented in fold induction relative to the respective untreated h-MDMs control. Results correspond to mean ± SEM of triplicates. Data are representative of  
three independent experiments. *p < 0.05, **p < 0.01 compared to the respective untreated control.
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Taken together, these data provided evidence that MR and 
dectin-1 are critical in fungicidal properties of h-MDMs medi-
ated by P17 and support the importance of AA/LTB4/PPARγ/
Dectin-1-MR axis in the strengthening of anti-fungal functions 
of h-MDMs by this HDP.
The interaction between P17 and gPcr 
controls anti-Fungal Properties of h-MDM 
via the induction of intracellular calcium 
Mobilization
Several studies demonstrated that HDPs induce intracellular 
calcium mobilization in immune cells (50–53). On this basis, 
we evaluated cytosolic calcium concentration in P17-activated 
h-MDMs. P17 treatment induced a significant augmentation 
of intracellular calcium concentration in h-MDMs, indicating 
that this HDP triggers intracellular calcium signal (Figure 4A). 
In order to determine the source of this calcium release, we 
assessed calcium mobilization in calcium-deprived medium 
to inhibit extracellular calcium influx (HBSS) and in the pres-
ence of U73122, an inhibitor of the intracellular pools calcium 
release. Interestingly, calcium mobilization was abolished both 
in presence of HBSS and U73122 (Figure 4A), suggesting that 
the P17-increase intracellular calcium concentration in h-MDMs 
was dependent on extracellular calcium influx and intracellular 
calcium stores mobilization.
Most of the HDPs immunomodulatory functions are mediated 
through GPCRs (27–29, 51). In order to evaluate the involvement 
of these receptors in the activation of h-MDMs mediated by P17, 
we used pertussis toxin (PTX), known to inhibit some GPCRs. 
PTX treatment totally inhibited the mobilization of calcium in 
P17-activated h-MDMs (Figure 4B), suggesting that P17 activity 
on h-MDMs was mediated by PTX-sensitive GPCR interaction. 
Interestingly, although PTX-sensitive fMLP receptors 1 and 2 
(FPR1 and FPR2) are the main GPCRs involved in the modula-
tion of immune response by HDPs, we demonstrated here that 
the desensitization of these receptors by the addition of fMLP did 
not affect P17-induced calcium mobilization (Figure 4C).
To investigate the role of P17-induced calcium mobilization in 
the fungicidal properties of P17-treated h-MDMs, we evaluated 
their capacity to kill the yeasts in the presence of an intracellular 
calcium chelator BAPTA-AM. The increase of ability to kill 
C. albicans of P17-activated h-MDMs was completely lost in 
the presence of BAPTA-AM (Figure  4D). These findings were 
consistent with the lack of induction of ROS and IL-1β produc-
tion in BAPTA-AM pretreated h-MDMs activated with P17 
(Figures 4E,F), further supporting that the intracellular mobiliza-
tion of calcium is essential in fungicidal properties of P17-treated 
h-MDMs. Altogether, these data highlight that P17 modulates 
anti-fungal immune response of h-MDMs through PTX-sensitive 
GPCR-triggered intracellular calcium mobilization.
FigUre 5 | P17 treatment of mice improves macrophage-intrinsic anti-fungal activities and restrains gastrointestinal fungal infection. (a) Body weight of untreated 
or P17-treated mice during Candida albicans gastrointestinal infection. (B) C. albicans GI colonization in cecum and colon of untreated or P17-treated mice 
determined on day 6 post-infection. C. albicans GI colonization in feces of untreated or P17-treated mice determined on days 4 and 5 post-infection. (c) Killing 
assay of peritoneal macrophages from untreated or P17-treated infected mice. Binding (D) and Phagocytosis (e) of C. albicans by peritoneal macrophages from 
untreated or P17-treated infected mice. Reactive oxygen species (ROS) (F) and interleukin (IL)-1β and IL-12 (g) production upon Candida challenge of peritoneal 
macrophages from untreated or P17-treated infected mice. Results correspond to mean ± SEM of triplicates. Data are representative of at least two independent 
experiments (n = 6 per group). *p < 0.05, **p < 0.01 compared to the respective untreated control.
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In Vivo P17 Treatment induces Fungicidal 
Properties of Macrophages hence 
improving the regression of 
gastrointestinal candidiasis
On the basis of the current findings demonstrating the micro-
bicidal activity of P17-treated h-MDM against C. albicans, we 
next explored whether the P17 treatment could have an impact 
on the in vivo candidiasis outcome. In this context, we evaluated 
the fungal burden in the intestinal tract and the macrophage 
microbicidal functions in a murine experimental model of gas-
trointestinal candidiasis. P17-treated mice (P17) infected with 
C. albicans developed less severe gastrointestinal infection than 
untreated mice (NaCl), as demonstrated by lesser weight loss and 
by reduced fungal burden as reflected by a decreased number 
of CFU in the colon, cecum, and feces of mice treated with P17 
(Figures 5A,B).
To investigate whether the effect of P17 on decreased Candida 
gastrointestinal colonization can be correlated to its impact on 
fungicidal functions of macrophages, we evaluated the capacity 
of macrophages from P17-treated mice to kill yeasts in  vitro. 
Compared to macrophages from untreated mice, macrophages 
from P17-treated mice showed an increase in their ability to kill 
C. albicans (Figure 5C). Consistent with our observation, mac-
rophages from P17-treated mice were more efficient in engulfing 
C. albicans and producing ROS and IL-1β (Figures  5D–G). 
Moreover, IL-12 release was similar in macrophages from 
untreated and P17-treated mice, demonstrating that P17 in vivo 
administration did not impact on IL-12 macrophage production 
(Figure 5G).
Taken together, these data provide in vivo evidence that P17 
improves macrophage-intrinsic anti-fungal activity and support 
that P17 may constitute promising compound to restrain gastro-
intestinal fungal infection.
DiscUssiOn
Although the majority of HDPs are currently known to exert 
antimicrobial activities against a broad spectrum of pathogenic 
microorganisms, they also can modulate the functions of 
immune cells (8). Among the two major groups of HDPs in 
humans, cathelicidins, and defensins, the LL-37 cathelicidin is 
the major AMP described for its immunomodulatory proper-
ties. Indeed, the LL-37 controls in several cells, particularly in 
human monocytes and murine macrophages, the transcription 
and the secretion of pro-inflammatory cytokines and chemokines 
(14–16, 18). Thus, the LL-37 participates to the immune cell 
differentiation, activation and chemotaxis (13, 54). Altogether 
these properties confer to LL-37 a strong microbicidal activity 
through its involvement in the control of inflammatory and anti-
infectious signaling in macrophages. These immunomodulatory 
functions on human and murine cells are also described for HDPs 
from arthropods, such as apidaecin, bee venom AMP, and venom 
peptides 7.2 and 7.8, parabutoporin and opistoporin, isolated 
from scorpion venom (25, 26, 55). Our team has recently isolated 
a new short HDP from T. bicarinatum ant venom, called P17. 
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Previous results demonstrated that this HDP shares common 
structural properties with LL-37. Indeed, structural studies of 
P17 revealed that this ant HDP, composed of 13 amino acids, 
is cationic, amphipatic, amidated in C-terminal position, and 
adopts an alpha helix conformation (31).
Here, we reported that the P17 influences phenotypic dif-
ferentiation of h-MDMs toward an alternative phenotype char-
acterized by a CLRs signature composed of MR and Dectin-1. 
Consistent with the key role of MR and Dectin-1 in yeast 
recognition, phagocytosis and clearance (35, 38, 56, 57), we 
demonstrated that the P17 increases the ability of h-MDMs to 
eliminate C. albicans. The involvement of MR and Dectin-1 in the 
P17-mediated anti-fungal activity of h-MDMs was further evi-
denced by the loss of Candida elimination in h-MDMs silenced 
for MR or Dectin-1. In line, the pre-treatment of P17-activated 
h-MDMs with soluble MR or Dectin-1 blocking agents, also 
severely compromised their capacity to bind and to kill C. albi-
cans. Consistent with the cooperative role of MR and Dectin-1 
in the induction of macrophage anti-fungal signaling pathways 
(34, 35, 37), we demonstrated that both MR and Dectin-1 are 
involved in the recognition of this yeast and in its subsequent 
elimination by P17-activated h-MDMs. Consistently, we 
showed that P17-activated h-MDMs is able to clear Leishmania 
infantum (Figures S1B,C in Supplementary Material), a parasite 
known to interact with macrophages through MR and Dectin-1 
(36). These results reveal that the immunomodulatory activity 
of P17 presents a broader spectrum, as long as the pathogen 
expresses on its surface carbohydrates recognized by MR or 
Dectin-1.
This study also provided the mechanistic insight into the 
transcriptional control of MR and Dectin-1 by P17 in h-MDMs. 
On the basis of the established role of PPARγ in the alterna-
tive activation and in the control of CLRs expression (34, 58), 
these findings identify PPARγ as a critical component in the 
signaling cascade that drives P17-mediated MR and Dectin-1 
overexpression.
In addition to the transcriptional increase of MR and Dectin-1 
in h-MDM by P17 treatment, we demonstrated that this HDP 
positively regulates the transcription of cPLA2, enzyme needed 
for AA release from membrane phospholipids, of 5-LOX, FLAP, 
and LTA4 hydrolase, critical for LTB4 synthesis. Consistent with 
this observation, the mobilization of AA and the generation of 
LTB4 by h-MDMs upon P17 treatment are strongly increased. 
Interestingly, the impairment of LTB4 production by a specific 
inhibitor of 5-LOX activation, completely abolishes the induc-
tion of MR and Dectin-1 mediated by P17, suggesting that P17 
controls MR and Dectin-1 expressions through the LTB4 release. 
Moreover, the fact that P17 increases MR-, Dectin-1-, and SRB1-
specific PPARγ target genes, similar to LTB4, and that the addition 
of both P17 and LTB4 did not show any additive effect on these 
gene inductions supports that P17 regulates MR and Dectin-1 
surface expressions by controlling PPARγ activation through the 
LTB4 production. This is reinforced by the finding showing that 
the inhibition of P17-induced MR, Dectin-1, and SRB1 PPARγ 
target gene expressions by MAFP, a specific inhibitor of AA 
release, was restored by the addition of LTB4. In agreement with 
the identification of LTB4 as PPARγ agonist in P17-mediated 
CLRs induction, numerous endogenous PPARγ ligands derived 
from the metabolism of AA are described (34, 35, 43, 48).
A significant contribution of this study was the identification 
of a novel signaling pathway triggered by an HDP involved in 
the antimicrobial response of macrophages. Indeed, the h-MDMs 
treated with PPARγ-specific antagonist, or with inhibitors of 
LTB4 synthesis, or silenced for MR or Dectin-1 failed to increase 
the killing of C. albicans in response to P17, establishing LTB4/
PPARγ/Dectin-1-MR axis as crucial in the acquisition of anti-
fungal properties of P17-treated h-MDMs.
Because ROS and pro-inflammatory cytokines are essentials 
Candida-killing components (35, 37, 39, 59, 60), we evaluated 
ROS and IL-1β release of h-MDMs upon P17 treatment and we 
investigated the signaling pathways involved in their production. 
Remarkably, the alternative phenotype of P17-treated h-MDMs 
is accompanied by an inflammatory signature characterized 
by IL-1β and ROS productions. In line, previous studies have 
highlighted the capacity of HDPs to simultaneously promote 
pro-inflammatory response while protecting host organism 
against exacerbated inflammatory response (18, 25, 26, 61–64). 
Consistent with the increased IL-1β production in P17-treated 
h-MDMs, the processing of pro-caspase-1 into its p20 subunit, 
which is a hallmark of caspase-1 activation (65), is augmented 
in P17-treated h-MDMs. Moreover, the involvement of P17 in 
ROS production is supported by large amounts of phosphoryl-
ated p47phox, a cytosolic subunit of the NADPH oxidase complex 
whose activation is essential to ROS release (66), in h-MDMs 
activated by P17. We also established that this LTB4/PPARγ/
Dectin-1-MR signaling drives ROS release in P17-treated 
h-MDMs, since the addition of GW9662, MAFP, and MK-886 
or the pre-treatment of P17-activated h-MDMs with soluble 
MR- and Dectin-1-blocking agents abolishes P17-mediated ROS 
production by h-MDMs in response to C. albicans. This is sup-
ported by previous reports identifying Syk-dependent ROS pro-
duction via Dectin-1 and MR receptors in fungal infection (67). 
Furthermore, we provided evidence for the major contribution of 
ROS production in IL-1β secretion by P17-activated h-MDMs in 
response to Candida. Consistent with these results, ROS produc-
tion activates IL-1β processing via caspase-1-dependent activity 
(49). Thus, we identified both MR and Dectin-1 as extracellular 
sensors for Candida recognition by P17-activated h-MDMs and 
the subsequent activation of the pro-IL-1β synthesis and ROS 
production. These oxidant agents are essential in inflammasome-
dependent IL-1β processing and hence in IL-1β production by 
P17-activated h-MDMs in response to Candida challenge. This is 
best supported by the fact that the induction of the Nlrp3 inflam-
masome complex activation is subjected to several events, such 
as the efflux of cellular potassium, the phagocytosis of particles, 
the generation of ROS, cathepsin B activation, and/or the vacu-
olar acidification (68–71).
Although we demonstrated with certitude that AA/LTB4/
PPARγ/CLRs/ROS-IL-1β signaling pathway is involved in the 
anti-fungal activity of P17-activated h-MDMs, we also showed 
that P17 increases significantly the mRNA level of LL-37 (data not 
shown), the only human cathelicidin-related AMP known to pro-
mote a pro-inflammatory response (15, 16). Thus, LL-37, in addi-
tion to ROS and IL-1β, could be an important component of the 
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anti-fungal activity of P17-activated macrophages. Interestingly, 
several studies show that PPARγ agonists promote the induction 
of cationic AMP expression (72). These observations support that 
the AA/LTB4/PPARγ axis triggered by P17 could also be involved 
in the production of LL-37.
One main implication of our study was the validation in vivo of 
the ability of P17 to modulate fungicidal activity of macrophages 
on a murine model of gastrointestinal candidiasis. The P17 treat-
ment rendered the mice less susceptible to gastrointestinal C. 
albicans infection by promoting macrophage-intrinsic anti-fungal 
activity. These data reveal the P17 as an effective immunomodula-
tory agent for anti-fungal functions of macrophages.
Finally, this study identified that the interaction between P17 
and GPCR is crucial in the induction of anti-fungal properties 
of h-MDMs by P17. Consistently, most HDPs control immune 
cells responses in a GPCR-dependent manner, mainly through 
fMLP receptors, such as FPR1 and FPR2 (27–29, 51). Although 
we demonstrated that P17 did not interact with fMLP receptors, 
this HDP engages PTX-sensitive GPCR, which is currently under 
identification. Moreover, in agreement with the involvement of 
calcium release in immunomodulatory activity triggered by many 
HDPs (50–53, 73), P17 modulates anti-fungal immune response 
of h-MDMs through PTX-sensitive GPCR-triggered intracellular 
calcium mobilization. As calcium signaling is an essential factor 
of cPLA2 activation in monocytes and macrophages (74, 75), P17 
could promote LTB4/PPARγ/Dectin-1-MR signaling pathway 
through the activation of cPLA2 and the subsequent AA release.
Taken together, all these data highlighted the immunomo-
dulatory activity of P17 on h-MDMs differentiation and their 
associated anti-fungal response. The identification of molecular 
mechanisms triggered by P17 responsible of increased micro-
bicidal response of h-MDMs against C. albicans revealed 
the importance of the AA/LTB4/PPARγ/Dectin-1-MR axis 
(Figure 6). Confronted to the emergence of many resistances to 
the usual anti-infectious agents, P17 could constitute a promis-
ing compound to fight against fungal infections. Thus, this work 
offers new therapeutic perspectives and supports the use of 
PAMs as immunomodulatory compounds to restrain infectious 
diseases.
eThics sTaTeMenT
Mononuclear cells were obtained from healthy blood donors 
(Etablissement Français du Sang, EFS Toulouse, France). 
FigUre 6 | Schematic illustration of the immunomodulatory activity of P17 on human macrophages. The identification of molecular mechanisms triggered by P17 
reveals that this peptide modulates anti-fungal immune response of human monocyte-derived macrophages (h-MDMs) through pertussis toxin (PTX)-sensitive 
G-protein-coupled receptor (GPCR)-triggered intracellular calcium mobilization. The increased calcium mobilization in P17-activated h-MDMs is essential in cPLA2 
activation and the subsequent arachidonic acid (AA) release. This AA mobilization and the promotion of AA metabolization to leukotriene B4 (LTB4) upon P17 
treatment are responsible of the peroxisome proliferator-activated receptor gamma (PPARγ)-dependent mannose receptor and Dectin-1 overexpression. The 
activation of AA/leukotriene B4 (LTB4)/PPARγ/Dectin-1–mannose receptor axis by P17 triggers reactive oxygen species (ROS) production and inflammasome-
dependent interleukin (IL)-1β release critical in fungicidal activity of P17-activated h-MDMs.
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